In an ever-changing industry, how can cell and gene therapy start-ups remain dynamic to new challenges to not only survive coming changes but thrive? Click to read more.
.jpg)
Spencer talks to to Vered Caplan, CEO at Orgenesis Inc. about how their Point Of Care (POC) Platform aims to shape the Cell and Gene Therapies (CGT) ecosystem and market. Click here to listen.
These revolutionary companies are changing the game when it comes to neurological drug development, and thanks to recent funding they could be on the market sooner than you think. Click to find out more.
Cell and gene therapy continues to provide a better standard of living for millions of people with serious health conditions. Click to find out about some of the most exciting and innovative start-ups in this space.
